Since PIK3CA mutations occur only in 10–15% of CRC patients, it was postulated that PIK3CA-mutations may be too restrictive, and this subpopulation alone cannot explain the benefits of aspirin on a greater proportion of CRC patients [33]. This evidence concerns the gene PIK3CA and colorectal carcinoma.